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ABSTRACT 
 
Lung cancer is the leading cause of cancer death worldwide.EGFR 
tyrosine kinase inhibitors (TKIs)gefitinib, erlotinib and afatinib, are approved 
in first line for metastatic Non-Small Cell Lung Cancer (NSCLC) with 
sensitizing epidermal growth factor receptor (EGFR) mutations. Intrinsic or 
acquired resistance to EGFR often related to RAS or secondary EGFR 
mutations, is a relevant clinical issue in NSCLC management. Although Src 
TK has been involved in such resistance in preclinical models, clinical 
development of Src inhibitors has been so far limited and unsuccessful in 
NSCLC therapy.   
To better define the molecular targets of the Src TKIs saracatinib, 
dasatinib and bosutinib, we used a variety of techniques including kinase 
assays, molecular modelling analysis, and in vitro/in vivo studies on NSCLC 
cell lines with different EGFR/RAS mutational profile and EGFR sensitivity to 
EGFR TKIs. 
Kinase inhibition assays supported by docking analysis demonstrated 
that all the compounds are able to directly inhibit not only Src, but also EGFR 
TK variants. However, in cell lysates only saracatinib efficiently reduced 
EGFR activation, while dasatinib was the most effective agent in inhibiting Src 
TK. Consistently, in EGFR-activating mutant, erlotinib sensitive cells, 
saracatinib showed anti-proliferative effects due to possible EGFR inhibition. 
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In EGFR wt/RAS mutant cells, poorly dependent on EGFR activation and thus 
erlotinib resistant, Src inhibition by dasatinib interfered with cell proliferation 
and signal transduction. Based on these assumptions, we tested the following 
combinations: in EGFR-addicted cells, saracatinib with anti-EGFR drugs. 
(erlotinib or cetuximab), and in RAS mutant, erlotinib resistant models, 
dasatanib with the MEK inhibitor selumetinib. These combinations were 
effective both in vitro and in nude mice, inhibiting tumor growth, prolonging 
mice survival and interfering with signal transduction. Importantly, the 
combination of saracatanib and cetuximab was effective also in condition of 
T790M dependent EGFR resistance.  
In conclusion, Src inhibitors may act with different mechanisms,  in 
NSCLC cell lines, depending on EGFR/RAS mutational profile. Integration of 
anti-Src agents with EGFR or MEK inhibitors could represent an effective 
therapeutic option for different cohorts of NSCLC patients. 
 
BACKGROUND 
Lung cancer (NSCLC) is the leading cause of cancer-related death 
worldwide (Siegel RL Cancer J Clin 2015). approximately 85% of lung cancer 
are histologically defined as non-small cancer (NSCLC) and the majority of 
patients present an advanced disease for which no curative treatments are 
available.   
The epidermal growth factor receptor (EGFR) is a well characterized 
mutated oncogene in NSCLC. Activation of the EGFR pathway may promote 
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tumor growth and progression, stimulating cancer cell proliferation, invasion 
and metastasis and inhibiting apoptosis. The most common activating 
mutations are in-frame-deletion in exon 19 or in exon 18 and the L858R point-
mutation in exon 21. Both types of mutationincrease the sensitivity of the 
tumor to anilinoquinazoline inhibitors of EGFR, mostlikely byrepositioning 
critical residues surrounding the ATP-binding cleft of the tyrosine kinase 
domain of the receptor, thereby stabilizing their interactions with both ATPand 
its competitive inhibitor(Lynch NEJM 2004; Paez Science 2004; Pao PNAS 
2004).Indeed, mutant EGFR kinase binds the TKIs more tightly than the wild-
type. These constitutive kinase activation are predominantly with 
adenocarcinoma histology and the EGFR tyrosine kinase inhibitors (TKIs) 
gefitinib, erlotinib and afatinib represent a relevant therapeutic option for 
NSCLC patients with EGFR activating mutations (Rosell Lancet Oncol 2011; 
Mok NEJM 2009; Sequist JCO 2013). Unfortunately,de novo resistance to 
TKIs is often observed and virtually all patients who initially respond 
ultimately develop acquired resistance. Mechanisms of de novo resistance 
include K-RAS (15-25%) or B-RAF (2-3%) mutations, alterations in the exon 
20 of the EGFR (∼50%), such as the T790M substitution, activation of 
phosphoinositide-3-Kinase (PI3K)/Akt or insulin-like growth factor 1 receptor 
(IGF-1R) signaling. Acquired resistance may depend on second-site EGFR 
mutations (50%; i.e. T790M), MET or HER2 amplification, PI3K mutations, 
activation of AXL, PI3K or IGF-1R pathways, small cell transformation.In 
about half of the cases, tumors biopsied after disease progressioncontain a 
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second-site mutation in the EGFR kinase domain. The most common (>90%) 
alteration involves a C→Tchange at nucleotide 2369 in exon 20, which results 
in substitution of methionine for threonine at position 790 (T790M). 
Thissubstitution is analogous to the BCR-ABL T315I change foundin patients 
with chronic myelogenousleukemias, who have developedacquired resistance 
to imatinib(GorreScience 2001). Based uponcrystal structure analyses, the 
EGFRT790M substitution may impairbinding of either gefitinib or erlotinib to 
the EGFR ATP-bindingpocket.The change could also alter the relative affinity 
of ATP versus drug.Like other drug-sensitizing EGFR mutations, the T790M 
changeby itself has been shown to increase kinase activity and 
oncogenicpotential when compared with wild-type protein(Yun PNAS 2008; 
PaoPLoS Med 2005; Zhang Nat Gen 2012; Gainor JCO 2013; Yu CCR 2013; 
Balak, Clin. Cancer Res. 2006; Kobayashi. N. Engl. J. Med. 2005; Godin-
HeymannCancer Res. 2007). Alternative strategies for the treatment of patients 
after failure of EGFR TKIs are considered high-priority areas of research 
(GridelliCLin Lung Cancer 2013). 
Although EGFR is generally activated through ligand binding and 
autophosphorylation of its cytoplasmic tail, it is well established that Src non-
receptor TK, one of the EGFR downstream transducers, is able to transactivate 
EGFR by phosphorylating tyrosine 845 (Y845); this event may contribute to 
full receptor activation (Tice PNAS 1999). Src is a member of SFKs that are 
non receptor tyrosine kinases (nRTKs) including Yes, Fyn, Lyn, Lck, Hck, Fgr, 
Blk and Yrk. Src can physically associate with activated EGFR, thus resulting 
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in conformational changes and Srcautophophorylation at tyrosine 416 (Y416) 
and transient activation. In turn, this activation leads to phophorylation of 
several targets including EGFR on tyrosine 845 (Y845), that results in the 
receptor ability to enhance EGFR-mediated signaling. Elevated SFK activity is 
found in human tumors, including lung cancer. Although its frequency of 
detection varied among the different subgroups, SFK phosphorylation was 
detected in all three histological subtypes examined (adenocarcinoma, 
squamous cell, and bronchioloalveolar cell), in both genders, and in all 
smoking categories.  
Based on this evidence, TKIs acting on Src family kinases (SFKs) such 
as saracatinib and dasatinib have been proposed as therapeutic agents for 
NSCLC; these drugs are small molecules ATP competitors that can target 
kinases beyond the SFKs, and these off-target effects could have biological 
relevance. Particularly, some studies have described the effect of 
saracatinib(Green MolOncol 2009; Mc Dermott PNAS 2007) or dasatinib (Li 
Nat ChemBiol 2010;Yoshida Clin Cancer Res 2014) on cancer cell lines 
carrying EGFR TK variants, either wild-type or mutants. SFK inhibition 
usually affects invasion of NSCLC cells but has variable effects on apoptosis. 
Inhibiting SFKs in NSCLC cell lines that have activating EGFR mutations 
leads to significant apoptosis. However, apoptosis is rarely observed in NSCLC 
cell lines that express wild-type EGFR. However, disappointing results from 
phase I/II clinical trials have so far delayed the clinical development of these 
drugs. Although all studies, conducted in prospectively unselected patients with 
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advanced NSCLC, showed poor activity of Src inhibitors either in first and 
subsequent lines of therapy, some isolated clinical response have been reported 
(Johnson JCO 2010; Haura JCO 2010; Johnson J Thor Oncol 2011; Laurie Clin 
Lung Cancer 2013). 
 
AIMS OF THE STUDY 
In the present study, we attempted to clarify the possible role of Src 
inhibitors in the context of NSCLC therapy. To this purpose, we used a variety 
of in vitro/in vivo assays aimed at better defining the molecular targets of 
saracatinib, dasatinib and bosutinib, the three most clinically investigated Src 
TKIs. Moreover, we tried to suggest the optimal combination regimens and the 
clinical settings where the different anti-Src agents may better exert their 
antitumor activity. 
 
MATERIALD AND METHODS 
Compounds.Cetuximab was kindly provided by ImClone Systems. 
Erlotinib, saracatinib, dasatinib, bosutinib and selumetinib were purchased 
from Selleck Chemicals, Germany.   
In vitro EGFR kinase inhibition assay. The EGFR kinase inhibition 
assay on saracatinib, dasatinib and bosutinib was performed with an EGFR 
kinase mutant profile screening service by ProQinase (ProQinase GmbH, 
Freiburg, Germany). Briefly, compounds were tested at 10 different 
concentrations (standard range: 3x10-10M–1x10-5M; semilog dilutions) against 
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wild type EGFR and then EGFR mutants and IC50 values were calculated. 
IC50values of EGFR reference inhibitor (gefitinib or erlotinib) were determined 
side-by-side. All assays were performed at the corresponding app. ATP Km of 
each protein kinase using the radiometric 33PanQinase Assay™. 
Docking of the Src inhibitors saracatinib, dasatinib and bosutinib 
in the EGFR tyrosine kinase domain.The three-dimensional (3D) structures 
of saracatinib, dasatinib, and bosutinib were drawn using the Builder tool and 
generated with Ligprep module within the Schrodinger package (Schrödinger, 
LLC: New York, NY, 2009). The Glide program, of the same package, was 
used to dock these compounds into the X-ray crystal structure of the EGFR 
tyrosine kinase domain (PDB 2ITT) (Yun Cancer Cell 2007). The receptor grid 
generation was performed for the box with a center in the putative binding site. 
The size of the box was determined automatically. The extra precision mode 
(XP) of Glide was used for the docking. The ligand scaling factor was set to 
1.0. The geometry of the ligand binding site of the complex between the 
selected ligands and the enzyme was then optimized. The binding site was 
defined as the ligand and all amino acid residues located within 8 Å from the 
ligand. All the protein residues located within 2 Å from the binding site were 
used as a shell. The following parameters of energy minimization were used: 
OPLS2005 force field; water was used as an implicit solvent; a maximum of 
5000 iterations of the Polak–Ribier conjugate gradient minimization method 
was used with a convergence threshold of 0.01 kJ 3 mol–1 Å–1. Molecular 
graphics were performed with the UCSF Chimera package. Chimera is 
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developed by the Resource for Biocomputing, Visualization, and Informatics at 
the University of California, San Francisco (supported by NIGMS P41-
GM103311). (PettersenJ Comput Chem. 2004). 
Cell cultures. Human HCC827, Calu3, H460, H1299, A549 and NSCLC 
cell lines were obtained from the American Type Culture Collection (ATCC). 
PC-9 and GLC82 cell lines were kindly provided by Dr F. Morgillo.Calu3-ER 
(Erlotinib Resistant) cells were established as previously described (Morgillo, 
Lung Can 2011). All cell lines were authenticated using DNA fingerprinting 
and maintained in RPMI medium supplemented with 10% heat-inactivated 
fetal bovine serum, 20 mM HEPES, pH 7.4, penicillin (100 IU/ml), 
streptomycin (100 µg/ml) and 4 mM glutamine (ICN, Irvine, UK) in a 
humified atmosphere of 95% air and 5% CO2 at 37°C. 
 Cell survival assay (MTT). Cells (104 cells/well) were grown in 24-
well plates and exposed for 72 hours to increasing doses of erlotinib, 
cetuximab, saracatinib, dasatinib or bosutinib, alone or in combination. The 
percentage of cell survival was determined using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT). The drug concentration producing 
50% survival inhibition was used as a marker of drug effect. 
Combination effect. The combination effect of two drugs was 
evaluated based on the combination index (CI), calculated using Calcusyn 
software (Biosoft, Cambridge, UK) and defined as follows: CI = (D)1/(Dx)1 + 
(D)2/(Dx)2 + (D)1(D)2/(Dx)1(Dx)2, where: (Dx)1 is the dose of Drug 1 alone 
required to produce an X% effect; (D)1 is the dose of Drug 1 required to 
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produce the same X% effect in combination with Drug 2; (Dx)2 is the dose of 
Drug 2 alone required to produce an X% effect; and (D)2 is the dose of Drug 2 
required to produce the same X% effect in combination with Drug 1. The 
combination effect was defined as follows: CI < 1, synergistic effect; CI < 0.5, 
highly synergistic effect; CI = 1, additive effect; and CI > 1, antagonistic 
effect. 
Immunoprecipitation and Western blot analysis. Total cell lysates 
from cell cultures or tumor specimens were resolved by 4-15% SDS-PAGE 
and probed with anti-human, polyclonal EGFR, monoclonal pMAPK, MAPK 
(Santa Cruz Biotechnology, Santa Cruz, CA), polyclonal pEGFR Y1173, pAkt, 
Akt, pSrc and Src (Cell Signaling Technologies, Beverly, MA), monoclonal 
actin (Sigma-Aldrich, Milan). Immunoreactive proteins were visualized by 
enhanced chemiluminescence (Pierce, Rockford, IL, USA). Densitometric 
analyses were performed with Image J software (NIH). 
Analysis of EGFR phosphorylation on Tyr845. Levels on pEGFR 
Y845 in cell protein extracts was analyzed by using PathScan® Phospho-EGF 
Receptor (Tyr845) Sandwich ELISA Kit (Cell Signaling Technologies, 
Beverly, MA), according to manufacturer’s instructions. 
RNA interference. Small interfering RNA (siRNA) against Src was 
obtained from Ambion Life Technology (Grand Island, NY, USA). A nonsense 
sequence was used as negative control. For siRNA validation, cells were 
transfected with Src siRNAs (5 and 50 nmol/L) using Lipofectamine 2000 
(Invitrogen) in Opti-MEM (Invitrogen); 24 or 48 hours after transfection, 
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Western blot analysis for Src protein expression was done. For the assessment 
of siRNA effects on cell survival and signaling, cells were transfected with Src 
siRNA for 24 hours, then treated with saracatinib, dasatinib or bosutinib for 3 
additional hours.  
Nude mice cancer xenograft models.Five weeks old Balb/c athymic 
(nu+/nu+) mice (Charles River Laboratories, Milan, Italy) maintained in 
accordance with institutional guidelines of the University of Naples Animal 
Care Committee were injected subcutaneously (s.c.) with HCC827 or H1975 
cells (107 cells/mice) re-suspended in 200 µL of Matrigel (CBP, Bedford, MA). 
After 7 days, tumors were detected and groups of 10 mice were randomized to 
receive: cetuximab 35 mg/kg intraperitoneally (i.p.) three times a week for 3 
weeks, erlotinib 20 mg/kg i.p. three times a week for 3 weeks, saracatinib 50 
mg/kg via oral gavage five times a week for 3 weeks,dasatinib 20 mg/kg i.p. 
three times a week for 3 weeks. Animals treated with DMSO vehicle served as 
controls. Tumor volume (cm3) was measured using the formula π/6 x larger 
diameter x (smaller diameter)2 as previously reported (Rosa Clin Can Res 
2013).  
Statistical analysis. The results of in vitro experiments were analyzed by 
Student’s t test and expressed as means and standard deviations (SDs) for at 
least three independent experiments performed in triplicates. The statistical 
significancewas determined by one-way ANOVA and Dunnett’s multiple 
comparison post-test regarding tumor growth, by log-rank test concerning mice 
survival (Rosa Clin Cancer Res 2013). Linear regression analysis for the 
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correlation between drug concentration producing 50% survival inhibition and 
Src activation was performed by using Sigma Plot ver. 11.0, as reported 
(Chang BMC Cancer 2013). All reportedP values were two-sided. Analyses 
were performed with the BMDP New System statistical package version 1.0 
for Microsoft Windows (BMDP Statistical Software, Los Angeles, CA).  
 
RESULTS 
Src inhibitors saracatinib, dasatinib and bosutinib are able to inhibit 
EGFR tyrosine kinase activation. 
Based on conflicting reports concerning the capability of Src inhibitors to 
directly affect EGFR tyrosine kinase activity (Green MolOncol 2009; Li Nat 
ChemBiol 2010; Mc Dermott PNAS 2007; Zhang Am J Pathol 2007; 
BoschelliEur J cancer 2010), we attempted to elucidate this point through an in 
vitro kinase assay comparing the effect of the Src inhibitors saracatinib, 
dasatinib and bosutinib with that of erlotinib on different EGFR tyrosine kinase 
variants, both wild-type and mutant. As indicated in Table 1, all the 
compounds were able to inhibit EGFR variants with IC50 values similar to 
erlotinib.Dasatinib seemed to be slightly less efficient than the other agents. 
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To better clarify how Src inhibitors could exert a direct effect on EGFR kinase, 
we evaluated whether these compounds could adapt in the EGFR kinase 
domain binding site. As shown in Figure 1, docking results demonstrated that 
all the three compounds are able to settle in the enzyme ATP active site, 
establishing several interactions with the protein. Interestingly, a well-oriented 
hydrogen-bond with the M793 residue of the hinge region is formed, further 
substantiating their ability to act as typical EGFR TKIs. 
 
 
Figure 1.Binding mode of saracatinib, dasatinib, and bosutinib in the EGFR kinase domain 
(PDB 2ITT) as predicted by docking calculations. The protein is depicted as cyan and white 
ribbons and surface, respectively. Key hinge region residue M793 is depicted as cyan sticks. 
Saracatinib, dasatinib, and bosutinib are represented as pink, orange, and yellow sticks, 
respectively. H-bond interactions are represented as dashed yellow lines. 
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Src inhibitors exert different effects on human Non-small Cell Lung 
Cancer (NSCLC) cell lines. 
In order to confirm the in vitro data, we used a panel of NSCLC cell lines with 
different levels of EGFR-dependent signaling activation and different degree of 
sensitivity against EGFR inhibitors. As shown in Table 2, this panel includes 
two cell lines with EGFR sensitizing mutations (A746_A750del), PC-9 and 
HCC827 (Terai H, Mol Cancer Res 2013); cell lines with wild-type EGFR, 
some of which harboring Ras or PI3K mutations and thus resistant to anti-
EGFR drugs (Calu3, H1299, H460, A549, GLC-82); and H1975 cells, showing 
a double EGFR mutation (L858/T790M) conferring resistance to EGFR 
inhibitors (Regales JCI 2009). We also included Calu3-ER, a cell line with 
acquired resistance to erlotinib that we obtained from Calu3 cells through a 
validated protocol of in vivo/in vitro selection (Morgillo F, Lung Can 2011); 
Calu3-ER cells display a significant increase in the expression of activated, 
phosphorylated MAPK compared to Calu-3 (Morgillo F, Br J Cancer 2011). 
The above described NSCLC cells showed different levels of activation of 
EGFR-dependent signaling, as proven by the variable expression of EGFR and 
activation of Src, Akt and MAPK (Figure 2). The observed levels are 
consistent with the mutational status of the cell lines and with previous data 
(Guo A, PNAS 2008; Morgillo F, Br Cancer 2011). 
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Figure 2. EGFR-dependent pathway activation in a panel of human NSCLC cell lines. 
Western blot analysis of protein expression in a panel of human NSCLC cell lines. 
 
When we tested Src inhibitors on these NSCLC models in comparison with 
erlotinib, we found that the three compounds have different effects on EGFR-
PC-9 HCC827 Calu-3 Calu3-ER H1299 H460 A549 GLC82 H1975 
EGFR 
pSrc 
Src 
pAkt 
Akt 
pMAPK 
MAPK 
Actin 
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dependent signal transduction. As shown in figure 3A, saracatinib was the 
most efficient, among the tested compounds, in reducing EGFR 
phosphorylation on Y1173, a well-known autophosphorylation site; this effect 
was more evident in EGFR mutant (PC-9 and HCC827) than in EGFR wild-
type (H1299) cells, similarly to that observed with erlotinib. Surprisingly, the 
effect was detected also in the EGFR double mutant H1975 cells, although at a 
very slight degree. Similar results were obtained also in the other NSCLC cells 
tested (Fig. 3B); H460 cells were poorly sensitive to all the tested drugs 
because of low EGFR and Src activation (data not shown). In all cell lines, 
dasatinib was the most effective agent in inhibiting Src TK activity (Fig. 3A 
and Fig. 3B). In EGFR wild-type cells, Src inhibition by dasatinib seemed to 
interfere with Akt and MAPK activation, while in the EGFR mutant cells a 
more relevant inhibition of these transducers was obtained with saracatinib 
and/or bosutinib (Fig. 3A and Fig. 3B).  
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Figure 3. Effects of Src inhibitors on signal transduction and survival of human NSCLC cell 
lines sensitive or resistant to erlotinib.  (A) Western blot analysis of protein expression in PC-
9, HCC827, H1975 and H1299 cells treated for 3 hours with erlotinib, saracatinib, dasatinib 
or bosutinib (1 µM). Densitometric analysis (D.a.): The relative optical density of phospho-
protein levels normalized to actin level is shown as histograms. *, 2-sided P< 0.05 versus 
control; **, 2-sided P< 0.01 versus control. (B)  Western blot analysis of protein expression in 
Calu3, Calu3-ER and A549 cells treated for 3 hours with erlotinib, saracatinib, dasatinib or 
bosutinib (1 µM). Densitometric analysis (D.a.): The relative optical density of phospho-
protein levels normalized to actin level is shown as histograms.*, 2-sided P< 0.05 versus 
control;**, 2-sided P< 0.01 versus control. 
 
Consistently with data from Western blot analysis, in EGFR-activating mutant, 
erlotinib sensitive PC-9 and HCC827 cells, saracatinib showed anti-
proliferative effects probably related to simultaneous EGFR/Src inhibition. 
Also in the EGFR double mutant model, saracatinib was slightly more effective 
than the other two compounds. Conversely, in EGFR wt/Ras mutant cells, 
poorly dependent on EGFR activation and thus erlotinib resistant, efficient Src 
inhibition by dasatinib interfered with cell proliferation (Fig. 3C, Fig. 3D and 
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Table 3). As a further confirmation, Src activation in NSCLC cells 
correlateswith sensitivity to dasatinib more than to saracatinib and bosutinib. 
Linear regression analysis (Chang and Wang BMC Cancer 2013) shown in 
figure 3E demonstrated that high levels of Src activation in NSCLC cells 
significantlycorrelate with high sensitivity to dasatinib (P = 0.0382). This 
correlation was not found with sensitivity to saracatinib and bosutinib (P> 
0.05). 
Figur
e 3D. Effects of Src inhibitors on signal transduction and survival of human NSCLC cell 
lines sensitive or resistant to erlotinib. (C)  Percent of survival of PC-9, HCC827, H1975 and 
H1299 cells treated for 72 hours with erlotinib, saracatinib, dasatinib or bosutinib (1 µM), as 
measured by MTT assay. Data represent the mean (±SD) of three independent experiments, 
each performed in triplicate. Bars, SDs. (D)Percent of survival of Calu3, Calu3-ER and A549 
cells treated for 72 hours with erlotinib, saracatinib, dasatinib or bosutinib (1 µM), as 
measured by MTT assay. Data represent the mean (±SD) of three independent experiments, 
each performed in triplicate. Bars, SDs. 
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Figure 3E.Correlation between growth inhibition by saracatinib, dasatinib or bosutinib and 
Src baseline activation. The correlation between the concentration of saracatinib, dasatinib or 
bosutinib producing 50% growth inhibition and the ratio of p-Src/actin in 9 human NSCLC 
cell lines was shown. Protein expressions were measured by western blot (see Figure 2) and 
analysed by ImageJ software.Linear regression analysis was performed by using Sigma Plot 
ver. 11.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
≥ ≥ ≥ 
p = 
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Table 3. P values for survival inhibition by saracatinib, dasatinib and bosutinib (treatment vs 
control) in human NSCLC cell lines sensitive or resistant to erlotinib, as measured by MTT 
assay.  
 
 
We attempted to confirm these data in HCC827 tumor xenografts. On day 63 
(9 weeks after tumor cells injection) all mice in the control group reached the 
maximum allowed tumor size of about 2 cm3. At this time point, dasatinib 
produced a tumor growth inhibition of about 27%, while erlotinib- and 
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saracatinib-treated mice appeared to be tumor free. These latter agents 
maintained a potent antitumor activity until the end of the experiment, with 
about 99% and 83% of growth inhibition for erlotinib and saracatinib, 
respectively. Comparison of tumor sizes among different treatment groups was 
statistically significant (Fig. 4A). Consistently, as shown in figure 4B, mice 
treated with erlotinib and saracatinib did not reach a median survival, since 
70% and 50% of the mice were still alive at the end of the experiment, 
respectively. Treatments were well tolerated; no weight loss or other signs of 
acute or delayed toxicity were observed. Western blot analysis on tumor 
samples from mice sacrificed on day 14, after 1 week of treatment, 
demonstrated that saracatinib is able to reduce EGFR phosphorylation similarly 
to that observed with erlotinib. Dasatinib was unable to do that (Fig. 4C). 
 
Figure 4. Effects of Src inhibitors on signal transduction and survival of human NSCLC cell 
lines sensitive or resistant to erlotinib.  (A) After 7 days following subcutaneous injection of 
HCC827 cells, mice were randomized (10/group) to receive erlotinib, saracatinib or dasatinib, 
as described in the Methods section. The one-way ANOVA testwas used to compare tumor sizes 
among treatment groups at the median survival time of the control group (42 days). They 
resulted statistically significant for all the drugs vs control (P< 0.0001). (B) Median survival 
did not result statistically significant for dasatinib versus control (log-rank test); mice groups 
treated with erlotinib or saracatinib did not reach a median survival, since 70% and 50% of 
animals were still alive at the end of the experiment, respectively. (C) Western blot analysis 
was performed on total lysates from tumor specimens of two mice sacrificed on day 14. Data 
A B C 
HCC827 tumor xenografts 
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represent the mean (±SD) of three independent experiments, each performed in triplicate, and 
are presented relative to control. Bars, SDs.  
 
Saracatinib and bosutinib exert a direct, not Src-mediated effect on 
EGFR.  
Based on the evidence that saracatinib and bosutinib are able to interfere with 
EGFR phosphorylation on Y1173 in NSCLC cell lines, we attempted to 
exclude that this effect could be mediated by Src inhibition.  
Since it is well known that Src can phosphorylate EGFR on Y845, we first 
verified the capability of Src inhibitors to interfere with this event through an 
ELISA assay measuring pEGFR Y845 levels. Saracatinib and dasatinib 
moderately inhibited EGFR phosphorylation on Y845 in PC-9, HCC827 and 
H1299 cells, while no effect was detected in H1975 cells (Fig.5A). However, it 
has been reported that Src phosphorylation on Y845 does not affect EGFR 
kinase activity (Tice PNAS 1999): so EGFR Y1173 phosphorylation should 
not be affected by Src inhibition, unless the inhibitors have cross-reactivity 
with the EGFR. Consistently, when we silenced Src expression in HCC827 
cells by using a specific siRNA, we found that phosphorylation of EGFR on 
Y1173 was not affected (Fig.5B). Treatment with saracatinib in presence of 
Src siRNA maintained its capability to reduce EGFR Y1173 phosphorylation, 
thus confirming that the effect on EGFR was direct and not Src-mediated; 
conversely, dasatinib had no effect on EGFR phosphorylation/activation also in 
presence of Src silencing (Fig.5B). 
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Figure 5. Correlation between drugs effect on human NSCLC cell lines and Src inhibition. 
(A) Percent of EGFR Tyr845 phosphorylation in PC-9, HCC827, H1975 and H1299 cells 
treated for 3 hours with erlotinib, saracatinib or dasatinib (1 µM), as measured by using the 
PathScan® Phospho-EGF Receptor (Tyr845) Sandwich ELISA Kit. *, 2-sided P< 0.05 versus 
control. Data represent the mean (±SD) of three independent experiments, each performed in 
triplicate. Bars, SDs. (B) Western blot analysis of protein expression in HCC827 cells 
transfected with a Src specific siRNA or with a negative control, and then treated (24 hours 
after transfection) with saracatinib or dasatinib for 3 hours. 
 
 
Cetuximab plus saracatinib is an effective combination in EGFR-addicted 
cells. 
In order to better define the role of Src and EGFR dependence, we tested Src 
inhibitors in combination with different classes of EGFR inhibitors. We first 
evaluated the combination of the most effective Src inhibitor (saracatinib for 
PC-9, HCC827 and H1975; dasatinib for H1299 cells) with the anti-EGFR 
drugs erlotinib(Figure 6A, B and  Table 4) or cetuximab (Figure 6C, D and  
Table 4), by MTT assays and Western blot analysis. In EGFR-addicted cells 
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(both erlotinib sensitive PC-9 and HCC827, and erlotinib resistant H1975 
cells), the best combination was saracatinib plus cetuximab, which is able to 
efficiently reduce cell survival (Figure 6C and  Table 4) and to interfere with 
EGFR and EGFR-dependent signal transducers activation (Figure 6D). The 
same effect was not obtained with dasatinib plus cetuximab in EGFR wild-type 
H1299 cells (Figure 6C, D and Table 4).  
 
 
 
Figure 6. Effects of the combinations of EGFR and Src inhibitors on signal transduction 
and survival of human NSCLC cell lines.(A) Percent of survival of PC-9, HCC827, H1975 
and H1299 cells treated for 72 hours with different concentrations of saracatinib (for PC-9, 
HCC827, H1975) or dasatinib (for H1299), alone or in combination with erlotinib, as 
measured by MTT assay. *, 2-sided P< 0.05 versus erlotinib alone; **, 2-sided P< 0.01 versus 
erlotinib alone. (B) Western blot analysis of PC-9, HCC827, H1975 and H1299 cells treated 
for 3 hours with saracatinib (for PC-9, HCC827, H1975) or dasatinib (for H1299), alone or in 
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combination with erlotinib. (C) Percent of survival of PC-9, HCC827, H1975 and H1299 cells 
treated for 72 hours with different concentrations of saracatinib (for PC-9, HCC827, H1975) 
or dasatinib (for H1299), alone or in combination with cetuximab, as measured by MTT assay. 
*, 2-sided P< 0.05 versus cetuximab alone; **, 2-sided P< 0.01 versus cetuximab alone. (D) 
Western blot analysis of PC-9, HCC827, H1975 and H1299 cells treated for 3 hours with 
saracatinib (for PC-9, HCC827, H1975) or dasatinib (for H1299), alone or in combination 
with cetuximab.  
Data represent the mean (±SD) of three independent experiments, each performed in triplicate. 
Bars, SDs. 
 
 
 
Cell line  D1  D2  D3  
PC-9  < 0.001  0.012  < 0.001  
HCC827  0.666  0.045  0.002  
H1975  0.176  0.070  0.140  
H1299  0.330  1.000  0.448  
 
 
Cell line  D1  D2  D3  
PC-9  < 0.001  0.008  0.015 
HCC827  0.003  0.006  0.004  
H1975  0.276  0.006  0.002  
H1299  0.739  0.011  0.013  
 
Table 4. P values for survival inhibition by Src inhibitor plus erlotinib (combination vs erlotinib) or 
cetuximab (combination vs cetuximab) in humans NSCLC cell lines, as measured by MTT assay 
 
Src inhibitor plus cetuximab 
Src inhibitor plus erlotinib 
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More interestingly, as shown in figure 7, the combination of cetuximab plus 
saracatinib resulted effective in vivo, in erlotinib resistant, EGFR double 
mutant H1975 tumor xenografts. On day 70 (10 weeks after tumor cells 
injection) all the mice in the control group reached the maximum allowed 
tumor size of about 2 cm3. At this time point, saracatinib produced a tumor 
growth inhibition of about 66%, while cetuximab and the combination reduced 
tumor growth of about 95%. Saracatinib-treated mice reached the size of 2 cm3 
on day 119, while mice treated with cetuximab or cetuximab plus saracatinib 
never reached this size. The combination of cetuximab and saracatinib caused a 
long-lasting cooperative antitumor activity, with about 95% of growth 
inhibition (vs 53% of cetuximab alone) until the end of the experiment. 
Comparison of tumor sizes among different treatment groups was statistically 
significant (Fig.7A). Consistently, as shown in figure 7B, mice treated with the 
combination did not reach a median survival, since 80% of the mice were still 
alive at the end of the experiment. Treatments were well tolerated; no weight 
loss or other signs of acute or delayed toxicity were observed. Western blot 
analysis on tumor samples from mice sacrificed on day 14, after 1 week of 
treatment, demonstrated that cetuximab plus saracatinib efficiently interferes 
with EGFR-dependent signal transduction, by reducing 
phosphorylation/activation of EGFR, Src, Akt and MAPK. The effect on 
EGFR is probably potentiated by EGFR down-regulation due to cetuximab-
induced internalization (Fig. 7C), as previously reported (Regales JCI 2009). 
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Figure 7. Effects of saracatinib plus cetuximab combination on tumor growth, survival and 
signal transduction of mice xenografted with H1975 erlotinib resistant tumors. (A) After 7 
days following subcutaneous injection of H1975 cells, mice were randomized (10/group) to 
receive cetuximab, saracatinib or their combination, as described in the Methods section. The 
one-way ANOVA testwas used to compare tumor sizes among treatment groups at the median 
survival time of the control group (38.5 days). They resulted statistically significant for the 
combination versus control or saracatinib (P< 0.0001). (B) Median survival resulted 
statistically significant for the saracatinib versus control (log-rank test); mice groups treated 
with cetuximab or with the combination did not reach a median survival, since 70% and 80% 
of animals were still alive at the end of the experiment, respectively. (C) Western blot analysis 
was performed on total lysates from tumor specimens of two mice sacrificed on day 14. Data 
represent the mean (±SD) of three independent experiments, each performed in triplicate, and 
are presented relative to control. Bars, SDs.  
 
 
 
Selumetinib plus dasatinib is an effective combination in Ras-dependent 
cells. 
Since the combinations of EGFR and Src inhibitors are poorly effective in 
EGFR wild-type, Ras mutant models, we hypothesized that MAPK signalling 
blockade could potentiate Src pharmacological inhibition. In fact, we found 
that combination of dasatanib with the MEK inhibitor selumetinib strongly 
inhibits cell survival in H1299 cells. Similar effects were observed in Calu3-
ER, a cell line with acquired resistance to erlotinib showing a significant 
increase in the levels of activated, phosphorylated MAPK (Fig. 8A and  Table 
5). The combination seemed to be highly synergistic, as demonstrated by the 
very low values of combination index (CI) devised by Chou and Talalay (Chou 
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and Talalay, Adv Enzyme 1984) using an automated calculation software 
(Table 6). Consistently, since dasatinib was able to reduce phosphorylation of 
Src and Akt, while selumetinib suppressed MAPK phosphorylation/activation, 
this effect was paired with a strong interference with signal transduction in 
both cell lines (Fig. 8B). The effectiveness of selumetinib was not observed in 
the Ras mutant A549 cell line (data not shown), as previously reported (Troiani 
Br J Cancer 2012). 
 
 
 
Figure 8. Effects of the combination dasatinib plus selumetinib on Ras-dependent human 
NSCLC models. (A) Percent of survival of H1299 and Calu3-ER cells treated for 72 hours 
with different concentrations of dasatinib, alone or in combination with selumetinib, as 
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measured by MTT assay. **, 2-sided P< 0.01 versus selumetinib alone. (B) Western blot 
analysis of H1299 and Calu3-ER cells treated for 3 hours with dasatinib, alone or in 
combination with selumetinib. 
Src inhibitor plus selumetinib 
Cell line  D1  D2  D3  
H1299  < 0.001  < 0.001  < 0.001 
Calu3-ER  < 0.001  0.006  0.002 
 
Table 5. P values for survival inhibition by Src inhibitor plus selumetinib (combination vs 
selumetenib) in Ras-dependent human NSCLC cell lines, as measured by MTT assay. 
 
 
 
 
Src inhibitor plus selumetinib 
Cell line  D1  D2  D3  
H1299  0.151  0.084 0.147 
Calu3-ER  0.201 0.011  0.003  
 
Table 6. P values for survival inhibition by Src inhibitor plus selumetinib (combination vs 
selumetenib) in Ras-dependent human NSCLC cell lines, as measured by Chou and Talalay 
method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
DISCUSSION 
 
Src inhibitors have been suggested as promising agents for NSCLC, but 
disappointing results from clinical trials have so far delayed their clinical 
development (Johnson JCO 2010; Haura JCO 2010; Johnson J Thor Oncol 
2011; Laurie Clin Lung Cancer 2013). A major limitation of these studies may 
have been the enrolment of molecularly unselected patients with advanced 
NSCLC and the lack of predictive biomarkers of response. In fact, populations 
of patients with different molecular features could benefit from the treatment 
with different Src inhibitors: despite these trials have been considered negative, 
some clinical responses have been reported. In the present study, we attempted 
to better define the mechanisms of action of the three Src TKIs (saracatinib, 
dasatinib and bosutinib) more extensively investigated in human cancer 
malignancies, in order to evaluate how these agents could be integrated in the 
context of NSCLC therapy.  
To this purpose, we used a variety of in vitro/in vivo assays aimed to 
clarify the molecular targets of the above cited agents. In fact, several studies 
have suggested that these ATP competitors can target kinases beyond the SFKs, 
including EGFR TK variants, either wild-type or mutants(Green MolOncol 
2009; Mc Dermott PNAS 2007; Li Nat ChemBiol 2010); however, this issue 
still remains controversial.By using an in vitro kinase assay we demonstrated 
that Src inhibitors are able to inhibit EGFR TK activation. Moreover, docking 
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studies suggested that all the three compounds are able to settle in the enzyme 
binding site, further confirming their ability to act as typical EGFR TKIs.  
When tested on human NSCLC cell lines, Src inhibitors showed 
different effects. In EGFR-activating mutant, erlotinib sensitive cells, 
saracatinib showed anti-proliferative effects probably related to simultaneous 
EGFR/Src inhibition. In fact, this agent seems the most efficient in inhibiting 
EGFR phosphorylation on Y1173 (a well-known autophosphorylation site), 
especially in presence of activating mutations. This result was confirmed also 
in vivo, in HCC827 tumor xenografts, where saracatinib showed a potent and 
long-lasting antitumor activity. This finding is of interest: in a recently 
published phase II clinical trial (Laurie SA, Clin Lung Cancer 2014), two 
partial responses were observed out of 31 NSCLC patients treated with 
saracatinib monotherapy; a long lasting responder had an EGFR exon 19 
deletion. Surprisingly, in contrast to erlotinib, saracatinib was proven to be also 
effective in the EGFR T790M mutant model. Conversely, in all cell lines, 
dasatinib was the most effective agent in inhibiting Src TK. In EGFR wild-type 
cells, Src inhibition by dasatinib seemed to interfere with Akt and MAPK 
activation, thus efficiently inhibiting cell proliferation. 
Saracatinib has been proven able to inhibit purified EGFR variants in a 
kinase assay; therefore, we attempted to rule out whether its effect on EGFR 
Y1173 phosphorylation observed in NSCLC cell lines may be mediated by Src 
inhibition. It is well known that Src can phosphorylate EGFR on Y845, but it 
has been reported that Src phosphorylation on this residue does not affect 
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EGFR kinase activity (Tice PNAS 1999): so, EGFR Y1173 phosphorylation 
should not be affected by Src inhibition, unless the anti-Src agents have cross-
reactivity with EGFR. Consistently, when we silenced Src expression in 
HCC827 cells, we found that phosphorylation of EGFR on Y1173 was not 
affected. Treatment with saracatinib in presence of Src silencing maintained its 
capability to reduce EGFR Y1173 phosphorylation. These data suggest that the 
effect observed in NSCLC cell lines after saracatinib treatment is not strictly 
Src-mediated.  
Altogether, these data suggest that the three compounds may act with 
different mechanisms in NSCLC cell lines: while dasatinib, as expected, 
functions via Src inhibition, saracatinib showed an additional mechanism of 
action based on direct EGFR inhibition. Bosutinib seemed to have an 
intermediate behavior, with a certain degree of variability among the different 
cell lines. As a further confirmation, Src activation in NSCLC cells correlated 
with sensitivity to dasatinib more than to saracatinib and bosutinib.  
In order to overcome resistance to EGFR inhibitors, we explored the 
optimal combination regimens and the settings where the different anti-Src 
agents may better exert their antitumor activity. In EGFR-addicted cells (either 
erlotinib sensitive or resistant), a very effective combination was saracatinib 
plus cetuximab. This result was confirmed also in erlotinib resistant, EGFR 
double mutant H1975 tumor xenografts, where this combination caused a 
strong cooperative antitumor activity and prolonged mice survival. 
Interestingly, the effect of saracatinib on EGFR was probably potentiated by 
 33 
 
EGFR down-regulation due to cetuximab-induced internalization, as previously 
reported (Regales JCI 2009). Targeting EGFR by using two different 
approaches, namely a monoclonal antibody directed against the extracellular 
portion of the receptor and a TKI able to interfere with ATP binding, has been 
proven effective in models of NSCLC harboring the T790M resistance 
mutation: together, these agents efficiently deplete both phosphorylated and 
total EGFR (Regales JCI 2009). The robust antitumor activity of afatinib and 
cetuximab combination has been demonstrated in a phase Ib clinical trial in 
advanced EGFR mutated NSCLC cancers, which progressed after EGFR TKI 
therapy: among 126 patients, high objective response rate (overall 29%) was 
reported, and resulted comparable in T790M-positive and T790M-negative 
tumors (Janjigian, Cancer Discovery 2014). This study supports the hypothesis 
that a significant proportion of tumors with acquired resistance to anti EGFR 
TKI remains dependent on EGFR signaling, and that combination therapies 
could have a significant impact in the clinical arena. However, it should 
pointed out that afatinib and cetuximab possess overlapping toxicities (mainly 
diarrhea and skin rush) that could limit their use in patients; by contrast, 
saracatinib, at least based on data from completed clinical trials, seems to have 
a different toxicity profile (Molina, Lung Can 2014). In addition, saracatinib 
offers the advantage of simultaneous Src inhibition, possibly providing a 
further benefit in terms of tumor growth control and preventing the onset of 
Src-mediated resistance to EGFR inhibitors, as previously reported (Zhang Nat 
Med 2011; Rexer Oncogene 2011; Formisano Breast Can Res 2014). 
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Therefore, our study may have relevant therapeutic implications for lung 
cancer patients, suggesting an effective strategy to overcome EGFR drug 
resistance.  
Conversely, in EGFR wild-type, Ras mutant models, combination of 
dasatanib with the MEK inhibitor selumetinib strongly inhibited cell survival 
and signal transduction, producing a highly synergistic effect. These data are of 
relevance based on the promising efficacy of selumetinib plus docetaxel 
combination reported in a randomized phase 2 clinical trial for K-Ras mutant 
advanced NSCLC (Janne, Lancet Oncology 2013). However, the higher 
number of adverse events observed with the combination than with docetaxel 
alone could suggest the search of other MEK inhibitors-based combination. In 
this respect, the relevance of Src in the onset of pharmacological resistance as 
well as the effectiveness of saracatinib in combination regimens has been 
recently highlighted also in ALK-positive NSCLC models (Crystal AS, 
Science 2014). 
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CONCLUSIONS 
We demonstrated that different Src inhibitors act through different 
mechanisms in NSCLC models sensitive or resistant to erlotinib. This evidence 
may partially justify the failure of clinical trials with Src inhibitors in 
unselected NSCLC patients (Johnson JCO 2010; Haura JCO 2010; Johnson J 
Thor Oncol 2011; Laurie Clin Lung Cancer 2013). The off-target effect, 
particularly on EGFR mutant variants, could be a main strength of saracatinib 
in the setting of erlotinib resistant patients with EGFR mutations. Moreover, 
based on their differential effects, Src inhibitors may better cooperate with 
EGFR or MEK inhibitors in NSCLCs. In this respect, since few therapeutic 
options are available for EGFR wild-type, Ras mutant NSCLC, the 
combination of dasatinib plus selumetinib may be a novel strategy potentially 
valuable in the clinical setting. 
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Cancer Therapy: Preclinical
Sphingosine Kinase 1 Overexpression Contributes to
Cetuximab Resistance in Human Colorectal Cancer Models
Roberta Rosa1, Roberta Marciano1, Umberto Malapelle2, Luigi Formisano1, Lucia Nappi1, Claudia D'Amato1,
Valentina D'Amato1, Vincenzo Damiano1, Gabriella Marfe6, Silvana Del Vecchio3, Antonella Zannetti3,
Adelaide Greco2,4, Alfonso De Stefano1, Chiara Carlomagno1, Bianca Maria Veneziani5,
Giancarlo Troncone2, Sabino De Placido1, and Roberto Bianco1
Abstract
Purpose: Although the anti–EGF receptor (EGFR) monoclonal antibody cetuximab is an effective
strategy in colorectal cancer therapy, its clinical use is limited by intrinsic or acquired resistance. Alterations
in the "sphingolipid rheostat"—the balance between the proapoptotic molecule ceramide and the
mitogenic factor sphingosine-1-phosphate (S1P)—due to sphingosine kinase 1 (SphK1) overactivation
have been involved in resistance to anticancer-targeted agents. Moreover, cross-talks between SphK1 and
EGFR-dependent signaling pathways have been described.
Experimental design:We investigated SphK1 contribution to cetuximab resistance in colorectal cancer,
in preclinical in vitro/in vivo models, and in tumor specimens from patients.
Results: SphK1 was found overexpressed and overactivated in colorectal cancer cells with intrinsic or
acquired resistance to cetuximab. SphK1 contribution to resistancewas supportedby thedemonstration that
SphK1 inhibitionbyN,N-dimethyl-sphingosine or silencing via siRNA in resistant cells restores sensitivity to
cetuximab, whereas exogenous SphK1 overexpression in sensitive cells confers resistance to these agents.
Moreover, treatment of resistant cells with fingolimod (FTY720), a S1P receptor (S1PR) antagonist, resulted
in resensitization to cetuximab both in vitro and in vivo, with inhibition of tumor growth, interference with
signal transduction, induction of cancer cells apoptosis, and prolongation of mice survival. Finally, a
correlation between SphK1 expression and cetuximab response was found in colorectal cancer patients.
Clin Cancer Res; 19(1); 138–47. 2012 AACR.
Introduction
In the last few years, cetuximab and panitumumab, 2
monoclonal antibodies (mAb) targeting the EGF receptor
(EGFR), have proven to be effective in combination with
chemotherapy or as single agents for treatment of metastatic
colorectal cancer (1). However, as is common in cancer
therapy, intrinsic or acquired resistance to anti-EGFR drugs
by different mechanisms has been widely observed (2).
Molecular alterations such as mutations in genes codifying
for EGFR-dependent signal transducers [K-Ras, B-Raf, phos-
phoinositide 3-kinase (PI3K), and PTEN] have been related
to primary refractoriness to cetuximab in colorectal cancer.
Other mechanisms, such as alternative signaling by different
tyrosine kinase receptors or induction of angiogenesis by
tumor-derived factors, could be also involved, particularly in
the onset of resistance over prolonged treatment (3). There-
fore, there is an urgent need to identify novel predictive
markers of response to cetuximab as well as to develop novel
therapeutic strategies for colorectal cancer patients with
intrinsic or acquired resistance to this agent.
Sphingolipids are a family of molecules enriched in lipid
rafts that contribute to their unique biochemical properties.
Sphingolipidmetabolites including ceramide, sphingosine,
ceramide-1-phosphate (C1P), and sphingosine-1-phos-
phate (S1P) have emerged as bioactive signalingmolecules,
with ceramide and sphingoid bases serving as activators of
cell death pathways whereas S1P and C1P primarily exert
mitogenic effects (4). Altered regulation of the S1P/cer-
amide ratio can lead to an imbalance in the "sphingolipid
rheostat" through which these sphingolipid metabolites
influence cell fate and tissue homeostasis. The balance of
thesemolecules is critically regulated by sphingosine kinase
(SphK), which converts sphingosine to S1P by phosphor-
ylation (5). Two SphK isoforms have been cloned and
characterized to date. SphK1, activated by a variety of
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growth factors, cytokines and mitogens, is upregulated in
many cancers, often correlating with higher clinical grade
and resistance to standard therapy (6, 7). Consistently,
interference with SphK1 activity by dominant-negative
mutants or competitive inhibitors such as N,N-dimethyl-
sphingosine (DMS), as well as inhibition of S1P bymAbs or
S1P receptors antagonists such as fingolimod (FTY720,
Novartis), blocks tumorigenesis and tumor angiogenesis
in cancer models (8). Moreover, recent studies showed that
alterations of ceramide/S1P rheostatmay be involved in the
regulation of resistance to both chemotherapeutics and
targeted agents (9–14).
On the basis of this evidence, and as several reports
showed cross-talks between SphK1 and EGFR-dependent
signaling pathways (15, 16), we analyzed the contribution
of sphingolipid rheostat alterations to cetuximab resistance
in human colorectal cancer models. Moreover, we investi-
gated the combination of cetuximab and fingolimod as a
therapeutic strategy potentially effective in colorectal can-
cers resistant to cetuximab.
Materials and Methods
Compounds
DMS was purchased from Sigma. Cetuximab was kindly
provided by ImClone Systems. Fingolimod was kindly
providedbyNovartis International AG(Basel, Switzerland).
Cell cultures
Human SW48, GEO, SW480, LS174T, HCT116, HT29,
and LoVo colorectal carcinoma cell lines were obtained
from the American Type Culture Collection. GEO-CR
(Cetuximab Resistant) cells were established as previously
described (17).
MTT survival assay
Cells (104 cells/well) were grown in 24-well plates and
exposed to increasing doses of cetuximab, DMS or fingoli-
mod, alone or in combination. The percentage of cell
survival was determined using the MTT.
Apoptosis assay
Apoptosis was quantified using the Annexin V-FITC apo-
ptosis kit (BD Biosciences).
Immunoprecipitation and Western blot analysis
Total cell lysates from cell cultures or tumor speci-
mens were resolved by 4% to 15% SDS-PAGE and probed
with anti-human, polyclonal pEGFR, EGFR and SphK1,
monoclonal phospho mitogen-activated protein kinase
(pMAPK), MAPK and S1PR1/EDG-1 (Santa Cruz Biotech-
nology), polyclonal pAkt, Akt and SphK1 phospho-Ser225
(Cell Signaling Technologies), and monoclonal actin (Sig-
ma-Aldrich). Immunoreactive proteins were visualized
by enhanced chemiluminescence (Pierce). Densitometry
analysis was conducted with Image J software (NIH).
Sphingosine kinase assay
SphK1 activity was measured by using Sphingosine
Kinase Activity Assay Kit (Echelon Biosciences; refs. 18, 19).
Quantification of S1P
Quantification of S1P from cell protein extracts, tumor
lysates, or mice sera by ELISA assay was conducted using a
validated S1P Assay Kit (Echelon Biosciences; refs. 20, 21).
Hairpin siRNA construct for Sphk1
Endogenous Sphk1 expression was downregulated with
sequence-specific pSilencer-siSphK1 851 (Clone1) and
1118 (Clone2), as previously described (22), as well as
with Silencer Select Validated siRNA s16957 and s16959. A
nonsense sequence was used as a negative control.
Transfection of human SphK1 in human cell lines
Human SphK1 (GenBank accession no. AF200328)
cDNA was cloned into pCMV6-AC-GFP vector (OriGene
Rockville). Transient transfections were conducted using
the Lipofectamine 2000 (Invitrogen).
Nude mice cancer xenograft models
Five-week-old Balb/c athymic (nuþ/nuþ) mice (Charles
River Laboratories) maintained in accordance with institu-
tional guidelines of the University of Naples Animal Care
Committee were injected subcutaneously (s.c.) with GEO-
CR cells (107 cells/mice) resuspended in 200 mL of Matrigel
(CBP). After 7 days, tumors were detected and groups of 10
mice were randomized to receive: Cetuximab 10 mg/kg
intraperitoneally (i.p.) 3 times a week for 3 weeks, fingo-
limod 2.5 mg/kg i.p. 3 times a week for 3 weeks, or the
combination. Tumor volume (cm3)wasmeasuredusing the
formula p/6  larger diameter  (smaller diameter)2 as
previously reported (23).
Morphologic and immunohistochemical analysis of
mouse and human tumor samples
The morphologic evaluation of necrosis grade was done
on hematoxilin/eosin stained 5-mm slides by a semiquan-
titative score (0: absence; 1: low level; 2: intermediate level;
and 3: high level). The presence of apoptotic cells was
Translational Relevance
In this study, we investigated the contribution of
sphingosine kinase 1 (SphK1) overexpression to cetux-
imab resistance, both intrinsic or acquired, in colorectal
cancer. In preclinical models with intrinsic or acquired
resistance, SphK1 inhibition through different appro-
aches partially restored sensitivity to cetuximab. The
effect of fingolimod, a clinically available antagonist of
sphingosine-1-phosphate receptor, in cetuximab-resis-
tant colorectal cancer models was also shown, both
in vitro and in vivo. Moreover, we observed a correlation
between SphK1 expression and cetuximab response in
metastatic colorectal cancer patients. Therefore, our data
support cetuximab plus fingolimod as a novel therapeu-
tic combination to be tested in the clinical setting for
cetuximab-resistant colorectal cancer patients.
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determined immunohistochemically on formalin fixed
paraffin embedded (FFPE) 5-mm tissue slides by analyzing
the expression of annexin V by the alkaline phosphatase
system (EnVision, DAKO).
SphK1 immunohistochemistry was carried out on FFPE
5-mm tumor tissue sections. Validation of antibodies (24, 25)
and analysis of SphK1 expression on FFPE colorectal cancer
tissues is described in the Supplementary Methods section.
Statistical analysis
The results of in vitro experiments were analyzed by
Student’s t test and expressed as means and SDs for at least
3 independent experiments conducted in triplicates. The
statistical significance was determined by 1-way ANOVA
and Dunnett’s multiple comparison posttest about tumor
growth, by log-rank test concerning mice survival. All
reported P values were 2-sided. Analyses were conducted
with the BioMeDical Package (BMDP) New System statis-
tical package version 1.0 for Microsoft Windows (BMDP
Statistical Software).
The results of immunohistochemical analysis on colo-
rectal cancer tissue specimens and the clinical parameters
were evaluated for statistical significance. SphK1 expression
patternwas analyzed as following: Level 3 (high expression)
versus levels 0 (no expression), 1 (low expression) and 2
(intermediate expression). A multivariate analysis was con-
ducted to evaluate the correlation of SphK1 levels and other
clinical/pathologic variables with response rate to cetuxi-
mab-based therapy (responders vs. nonresponders).
Patients were classified as "responders" in case of complete
or partial response, and as "nonresponders" in case of stable
or progressive disease. k2 test and logistic regression were
used. Estimation of likelihood events for disease progres-
sion or death was calculated according to Kaplan–Meier.
Statistical differences between curves were calculated using
the log-rank test. HR and OR were assessed by multivariate
analysis. A P value of 0.05 or less was considered statistically
significant. All the analyses were conducted using IBM SPSS
Statistics 18 package software (SPSS Inc.).
Results
SphK1 is overexpressed and overactivated in human
colorectal cancer cell lines resistant to cetuximab
On the basis of the suggested correlation between SphK1
and resistance to anticancer-targeted agents (9–14), we
analyzed SphK1 expression in a panel of human colorectal
cancer cell lines, both sensitive or resistant to cetuximab.
They include SW48 cells, harboring a wild-type K-Ras gene;
GEO cells, positive for a K-Ras mutation (Gly12Ala);
the cetuximab-resistant derivative GEO-CR cells; SW480,
LS174T, HCT116, and LoVo cells, harboring K-Ras muta-
tions (Gly12Val for SW480; Gly12Asp for LS174T, and
Gly13Asp for HCT116 and LoVo); and HT29 cells, positive
for a B-Raf mutation (Val600Glu). As shown in Supple-
mentary Fig. S1A and S1B, cetuximab inhibited survival and
induced apoptosis more efficiently in SW48 and GEO than
in the other cell lines. These data are consistent with the K-
Ras or B-Raf status of the cell lines, except for GEO cells
which are sensitive to cetuximab despite the K-Ras muta-
tion, as reported by our and other groups (19, 26).
When analyzed by Western blot analysis, levels of SphK1
protein, as well as of its activated/phosphorylated form
(SphK1 phospho-Ser225), were observed to be higher in
cetuximab-resistant cells compared with cetuximab-sensitive
cells. Among the resistant cell lines, low levels of SphK1
expression/activation were detected only in HCT116 cells
(Fig. 1A), as previously reported (27). Consistently, SphK1
enzymatic activity (Fig. 1B), as well as levels of S1Pmeasured
in cell lysates (Fig. 1C), were higher in cells with intrinsic or
acquired resistance to cetuximab. Lower SphK1 activity and
S1P levels were detected in HCT116 cells (Fig. 1B and C).
We then tested sensitivity of colorectal cancer cell lines to
DMS, a potent competitive inhibitor of SphK1.Consistently
with the previous finding, higher doses ofDMSwere needed
to achieve complete enzyme saturation and survival inhi-
bition in resistant cells (Fig. 1D). Moreover, the proapop-
totic molecule ceramide, a precursor of sphingosine,
induced apoptosis less efficiently in resistant than in sen-
sitive cells, consistently with the idea that increased SphK1
levels mediate S1P synthesis by ceramide in resistant cells.
Also in this case, the only exception was the HCT116 cell
line (Fig. 1E). As a confirm of SphK1 overactivity, SphK1
inhibition by DMS potentiated the effects of ceramide in
resistant GEO-CR and SW480 cells, with a 2-fold increase in
apoptosis after combined treatment compared with cer-
amide alone (Fig. 1F).
SphK1 inhibition partially restores sensitivity to
cetuximab in resistant colorectal cancer cell lines
On the basis of the overexpression of SphK1 in resistant
cells, we investigated the involvement of this kinase in
cetuximab resistance by conducting combined treatment
of GEO-CR, SW480, LS174T, HT29 and LoVo cells with
DMS and cetuximab. DMS was able to significantly restore
sensitivity to cetuximab in resistant cells (Supplementary
Fig. S2A). Most interestingly, whereas neither DMS or
cetuximabwere able to produce significant apoptosis induc-
tion in resistant cells, the combination of these agents was
effective; this result was comparable to that obtained with
cetuximab alone in sensitive cells (Supplementary Fig. S2B).
These data show that SphK1 blockade may restore cetux-
imab activity in resistant cancer cells.
We also studied the effects of modulating SphK1 expres-
sion in resistant cancer cell lines. SphK1 gene silencing via
siRNA in GEO-CR, SW480, HT29, and LoVo SphK1-over-
expressing resistant cells caused a marked decrease in
SphK1 protein expression (Fig. 2A and Supplementary Fig.
S3A). SphK1 silencing was not achieved in LS174T cells due
to low transfection efficiency (data not shown). In all the
tested cells, treatment with SphK1 siRNA led to reduced
Akt phosphorylation/activation (Fig. 2A and Supplemen-
tary Fig. S3A), SphK1 enzyme activity (Fig. 2B) and S1P
production (Supplementary Fig. S3B). Moreover, as shown
in Fig. 2C, SphK1 silencing increased sensitivity to cetux-
imab-induced apoptosis in resistant cells. Conversely,
SphK1 overexpression in GEO and SW48 sensitive cells
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through a full-length expression vector increased SphK1
and SphK1 phospho-Ser225 protein levels (Fig. 2D and
Supplementary Fig. S3C), enzyme activity (Fig. 2E), and S1P
production (Supplementary Fig. S3D). As a further confirm,
SphK1 overexpression significantly prevented cell death in
response to cetuximab in GEO/SphK1 and SW48/SphK1
cells compared with controls. Moreover, in these cells,
SphK1 inhibition by DMS significantly restored sensitivity
to cetuximab-induced apoptosis (Fig. 2F).
The S1PR antagonist fingolimod restores sensitivity to
cetuximab in colorectal cancer cell lines
To further assess the role of SphK1 in cetuximab resis-
tance,we used fingolimod (FTY720), a S1PR antagonist that
could also act as a SphK1 inhibitor. This drug is currently
available for the treatment ofmultiple sclerosis (28) andhas
showed anticancer properties in different models of human
cancers (8, 29, 30). This agent moderately inhibits survival
of all cell lines, with an IC50 5 mmol/L (data not shown).
Then we evaluated fingolimod capability to restore cetux-
imab activity in resistant cells. As shown in Fig. 3A and B,
fingolimod significantly potentiated survival inhibition and
apoptosis induction by cetuximab in GEO-CR, SW480,
HT29, and Lovo cells. Therefore, we analyzed the effect of
the combination cetuximab plus fingolimod on SphK1
enzymatic activity and S1P production. In all cell lines,
cetuximab did not affect SphK1 activity and S1P levels,
while fingolimod reduced them. Statistically significant
reductions of SphK1 enzymatic activity and S1P levels were
detected with the combined treatment (Fig. 3C, D). Finally,
we investigated the activation of EGFR signal transducers
mainly involved in the onset of resistance to cetuximab. In
4 different resistant cells, cetuximab was ineffective in
inhibiting Akt and/or MAPK phosphorylation. Fingolimod
produced a variable effect, whereas the combined treat-
ment strongly interfered with both Akt and MAPK phos-
phorylation/activation in all cell lines (Fig. 3E).
Fingolimod restores sensitivity to cetuximab in
colorectal cancer xenografts in nude mice
To confirm the antitumor effect of the combination
fingolimod plus cetuximab also in in vivo models of cetux-
imab resistance,we xenograftedGEO-CR cells in nudemice.
On day 70 (10 weeks after tumor cells injection) all the
mice in the control group reached the maximum allowed
tumor size of about 2 cm3. GEO-CR tumors treated with
cetuximab initially responded to this agent, but then
resumed an exponential growth rate, reaching 2 cm3 on
day 91. Fingolimod inhibited growth of tumors that did not
reach the size of 2 cm3 until the end of the experiment, on
Figure 1. Overexpression and overactivation of SphK1 in human colorectal cancer cell lines resistant to cetuximab. A, Western blot analysis of SphK1 and
SphK1 phospho-Ser225 expression. Bottom shows the relative optical density of pSphK1 (Ser225) and SphK1 normalized to the actin level. B, SphK1
activity was measured by using SphK1 Activity Assay Kit. C, levels of S1P production (mmol/L), as measured by ELISA assays on cell lysates. D, percentage
of survival of cells treated with increasing doses of DMS (0.1–5 mmol/L), as measured by the MTT assay. , 2-sided P < 0.005 versus control. Bars,
SDs. E, percentage of apoptosis of cells treated with ceramide (10 mmol/L), as measured by the annexin V assay. , 2-sided P < 0.005 versus control.
F, percentage of apoptosis of GEO-CR and SW480 cells treated with ceramide (10 mmol/L), DMS (1 mmol/L), or the combination, as measured
by the annexin V assay. , 2-sided P < 0.005 versus ceramide alone. Data represent the mean (SD) of 3 independent experiments, each conducted
in triplicate. Bars, SDs.
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day 105. The combination of cetuximab and fingolimod
caused a potent and long-lasting cooperative antitumor
activity, with about 70% of growth inhibition (tumor size
of 0.6 cm3) until day 105, 11 weeks after treatment with-
drawal. Comparison of tumor sizes among different treat-
ment groups was statistically significant (Fig. 4A). Consis-
tently, as shown in Fig. 4B, mice treated with the combi-
nation showed a statistically significantly prolonged medi-
an survival duration compared with the controls [median
survival 102.5 vs. 37.50 days; HR, 0.07552; 95% confidence
interval (CI), 0.02130–0.2677; P < 0.0001] or to mice
treated with cetuximab as single agent (median survival
102.5 vs. 57; HR, 0.1570; 95% CI, 0.04962–0.4966; P ¼
0.0016). Treatments were well tolerated; no weight loss or
other signs of acute or delayed toxicity were observed
(Supplementary Table S1).
Western blot analysis on tumor samples frommice sacri-
ficed on day 25 showed that fingolimod not only inhibits
phosphorylation of SphK1 on Ser225, but efficiently inter-
feres also with EGFR-dependent signal transduction, by
reducing EGFR-, Akt-, andMAPK-activated forms. The com-
bination was more efficient than fingolimod alone, pro-
ducing an almost total suppression of EGFR and Akt phos-
phorylation/activation. No alterations in expression of
SphK1 and S1PR1 were detected (Fig. 4C). ELISA assays on
tumor lysates and mice sera revealed that fingolimod sig-
nificantly reduces S1P production by tumor cells, but the
combined treatment was much more effective (Fig. 4D).
On the basis of the proapoptotic effect observed in vitro
with the combination of cetuximab and fingolimod, we
conducted imaging of apoptosis in GEO-CR tumor-bearing
nude mice, 72 hours after the first treatment. As shown in
Figure 2. Effects of SphK1 modulation on cetuximab sensitivity in resistant colorectal cancer cell lines. A, Western blot analysis of protein expression in
GEO-CR, SW480, HT29, and LoVo cells transfected with an SphK1-speciﬁc siRNA or with a negative control. B, SphK1 activity was measured in cells
transfected with a SphK1 speciﬁc siRNA or with a negative control by using SphK1 Activity Assay Kit. , 2-sided P < 0.005 versus cells transfected with the
negative control. C, percentage of apoptosis of cells transfected with a SphK1 speciﬁc siRNA or a negative control and treated with cetuximab (140 nmol/L),
as measured by the annexin V assay. , 2-sided P < 0.005 versus cells transfected with the SphK1 speciﬁc siRNA, but untreated with cetuximab. D,
Western blot analysis of protein expression inGEOandSW48 cells transfectedwith humanSphK1 cDNA or an empty vector. E, SphK1 activity wasmeasured
in cells transfected with human SphK1 cDNA or an empty vector by using SphK1 Activity Assay Kit. , 2-sided P < 0.005 versus cells transfected with
the empty vector. F, percentage of apoptosis of cells transfectedwith human SphK1 cDNA or an empty vector and treated with cetuximab (140 nmol/L), DMS
(1 mmol/L), or the combination, as measured by the annexin V assay. , 2-sided P < 0.005 versus cetuximab alone. Data represent the mean (SD) of 3
independent experiments, each conducted in triplicate. Bars, SDs.
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Supplementary Fig. S4, a relevant apoptosis induction was
detected in mice treated with the combination compared
with mice treated with cetuximab or fingolimod as single
agents. We also investigated the long-term induction of
apoptosis by conducting immunohistochemical analysis
of annexin V on tumor samples from mice sacrificed on
day 25: a relevant staining was found only in tumors treated
with both cetuximab and fingolimod (Fig. 5A). Moreover,
the necrosis grade was low in the control, intermediate in
the cetuximab- or fingolimod-treated tumors, and high in
the combination-treated tumors (Fig. 5B).
SphK1 expression is related to cetuximab response in
colorectal cancer patients
On the basis of this body of data, and as alterations of
ceramide/S1P rheostat mediated by SphK1 overexpression
have been involved in reduced response to therapy in
human cancers (9–12, 14), we evaluated SphK1 expression
in paraffin-embedded, archived clinical tumor tissue speci-
mens obtained from 50 cases of K-Ras wild-type colorectal
cancer patients enrolled in controlled clinical trials and
treated with cetuximab-containing regimens. To evaluate
SphK1 expression, 3 different Abs were tested, but only one
yielded a strong signal intensity (Supplementary Fig. S5A).
This polyclonal Ab was validated for specificity and repro-
ducibility by using a previously described algorithm (25).
Briefly, it showed a band of the expected molecular weight
in Western blot analysis, produced a specific and localized
staining when titered on tissue microarray containing con-
trol tissues, and was reproducible between different runs
and lots (Supplementary Fig. S5B and S5C).
Representative pictures of samples with different SphK1
expression levels are shown in Supplementary Fig. S6A. As
reported in Table 1, 22 of the 50 tumor samples (44%)
expressed high levels of SphK1. Among them, 19 (87%)
derived from patients who did not respond to cetuximab-
based therapy. Statistical analysis showed that the correla-
tion between high levels of SphK1 expression and poor
response to cetuximabwas significant (P¼0.03).Moreover,
as shown in Supplementary Fig. S6B, progression free
survival (PFS) seemed in favor of patients with low levels
of SphK1 expression, with an advantage of 2.4 months
Figure 3. Effects of the S1PR antagonist ﬁngolimod on cetuximab sensitivity in colorectal cancer cell lines. A, percentage of survival of cells treated with
increasing doses of cetuximab (7–350 nmol/L), in presence or not of ﬁngolimod (1 mmol/L), as measured by the MTT assay. , 2-sided P < 0.005 versus cells
treated with cetuximab alone. B, percentage of apoptosis of cells treated with cetuximab (140 nmol/L), ﬁngolimod (5 mmol/L), or the combination, as
measured by the annexin V assay. , 2-sided P < 0.005 versus control. C, SphK1 activity was measured by using SphK1 Activity Assay Kit. , 2-sided
P < 0.05 and , 2-sided P < 0.005 versus untreated control cells. D, percentage of S1P production, as measured by ELISA assays on cell lysates. , 2-sided
P < 0.05 versus control. E, Western blot analysis of protein expression on GEO-CR, SW480, HT29, and LoVo cells treated for 24 hours with cetuximab
(140nmol/L), ﬁngolimod (1mmol/L), or the combination. Data represent themean (SD) of 3 independent experiments, eachconducted in triplicate. Bars, SDs.
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(median PFS 23.6 vs. 14.0 weeks, P¼ 0.05). Despite a trend
in favor of patients with low SphK1 levels, the difference in
terms of overall survival (OS) did not reach the statistical
significance (median OS 144.9 vs. 82.7 weeks, P¼ 0.5; data
not shown). To exactly delineate the role of SphK1 expres-
sion as a predictive/prognostic marker in the cohort of
patients presented, a multivariate analysis was conducted
including other potential confounding factors, such as
chemotherapy line, type of cetuximab-containing regimen,
tumor stage at the time of diagnosis. As reported in Sup-
plementary Table S2, SphK1 expression was the only factor
showing a statistically significant correlation with response
to cetuximab (P ¼ 0.03).
Overall, these data support the hypothesis that SphK1
expression may correlate with resistance to EGFR targeted
therapy in colorectal cancer patients.
Discussion
Although a number of molecular alterations have been
identified as responsible for resistance to EGFR inhibitors
available in clinical practice, such as cetuximab for colo-
rectal cancer, each of these mechanisms only partially
justifies the lack of response in patients. Therefore, the
search for further determinants of resistance may help to
better select patients potentially responsive to cetuximab
and to develop novel therapeutic strategies for resistant
cancers (1, 2).
On the basis of the evidence that alterations of ceramide/
S1P rheostat may be involved in resistance to biologic
agents (9, 13, 14) and as some reports showed cross-talks
between SphK1 and EGFR-dependent pathways (15,
16, 31), we investigated the role of SphK1 in the onset of
resistance to cetuximab in colorectal cancers. To this aim,we
analyzed SphK1 expression and activation in preclinical
models of colorectal cancer, both sensitive orwith intrinsic/
acquired resistance to cetuximab. We found that SphK1 is
overexpressed and overactivated in colorectal cancer cell
lines resistant to cetuximab. In fact, high expression of the
activated form of SphK1, produced by MAPK-mediated
phosphorylation on Ser225 (32), as well as high levels of
enzyme activity and S1P production, were detected in
resistant cells. Then, we investigated whether SphK1 inhi-
bition could restore cetuximab sensitivity in resistant cancer
cells. To this aim, we used different approaches, including
DMS, a potent, even if not specific (33), competitive inhib-
itor of SphK1, the S1PRs antagonist fingolimod, and siRNAs
Figure 4. Effects of the combination cetuximab plus ﬁngolimod on tumor growth, survival, and signal transduction ofmice xenografted with GEO-CR resistant
tumors. A, after 7 days following subcutaneous injection of GEO-CR cells, mice were randomized (10/group) to receive cetuximab, ﬁngolimod, or their
combination, as described in the Materials and Methods section. The 1-way ANOVA test was used to compare tumor sizes among treatment groups at the
median survival time of the control group (35 days). The results were statistically signiﬁcant for the combination versus single agents (P < 0.0001). B, median
survival was statistically signiﬁcant for the combination versus control or cetuximab (log-rank test). C, Western blot analysis was conducted
on total lysates from tumor specimens of 2 mice sacriﬁced on day 25. D, quantiﬁcation of S1P (mmol/L) on tumor lysates and mice sera by ELISA assays.
, 2-sided P < 0.05 and , 2-sided P < 0.005 versus control. Data represent the mean (SD) of 3 independent experiments, each conducted in triplicate,
and are presented relative to control. Bars, SDs.
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specific for SphK1. By combining each of these tools with
cetuximab on resistant cells, we showed that SphK1 inhi-
bition was able to partially restore cetuximab capability to
affect cell survival, apoptosis and EGFR-dependent signal
transduction. We particularly focused on signal transducers
classically involved in the development of resistance to
EGFR inhibitors, such as the PI3K/Akt/mTOR and the
Ras/mitogen-activated protein–extracellular signal-regulat-
ed kinase/MAPK pathways: The combination of cetuximab
with fingolimod produced a strong suppression of Akt and
MAPK phosphorylation/activation in resistant cells. These
results are consistent with other studies showing the capa-
bility of S1P to induce cell proliferation and survival
through activation of the Akt pathway (34–36). Most
importantly, the resensitization to cetuximab induced by
SphK1 inhibition was observed in different models of
resistance: SW480, HT29, and LoVo cells, whose intrinsic
resistance to cetuximab is related to K-Ras or B-Raf muta-
tions and consequent overactivation of the Ras/MAPK
pathway, and GEO-CR cells, whose acquired resistance is
due to PI3K/Akt overactivation (17).
It has been described that S1P produced by SphK1 may
function as a second messenger inside the cell or may be
secreted to bind to S1PRs on the cell surface. This signaling,
involved in several human diseases including cancer, is
defined as "inside-out" S1P signaling (37, 38). Therefore,
the resensitization to cetuximab that we observed in our cell
models may depend on cross-talks of EGFR pathway with
both intracellular S1P and/or extracellular S1P/S1PRs sig-
naling pathways. By comparing the effects of SphK1 and
S1PRs inhibitors, we attempted to explain this point and
discriminate between intracellular and extracellular effects
of S1P. Fingolimod has been initially defined as a S1PRs
antagonist: its phosphorylated form, produced by SphK2,
binds to S1PRs and elicits their polyubiquitination, endo-
cytosis, and degradation (39). In this study, we observed no
alteration in S1PR1 protein expression after treatment of
GEO-CR xenografts with fingolimod. This result seems to
rule out that the effect of fingolimod depends on its
Figure 5. Effects of the combination cetuximab plus ﬁngolimod on apoptosis and necrosis of GEO-CR tumor xenografts. A, immunohistochemical analysis
of the apoptotic marker annexin V on FFPE 5-mm tissue slides. B, morphologic evaluation of necrosis-grade on hematoxilin/eosin stained 5-mm slides.
Table 1. Correlation of SphK1 expression with
response to cetuximab-based therapy in
colorectal cancer patients
Cross tabulation response versus SphK1
SphK1
Low
expression
High
expression Total
Response Responders 11 3 14
Nonresponders 17 19a 36
Total 28 22 50
aP ¼ 0.03 vs. responders group.
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antagonistic activity on S1PRs. However, it has been
described that fingolimod can act also as a SphK1 inhibitor
(29). Therefore, the resensitization to cetuximab in our cell
models may depend on cross-talks of EGFR pathway with
intracellular S1P signaling rather than with extracellular
S1P/S1PRs signaling pathways. Further investigations are
needed to clarify this point.
As several preclinical studies reported the activity of
fingolimod in human cancer models (8), the antitumor
effect of this agent in colorectal cancers with acquired
resistance to cetuximab was investigated also in vivo, in
nude mice xenografted s.c. with GEO-CR cells. The combi-
nation of cetuximab and fingolimod caused a potent and
long-lasting cooperative antitumor activity, with inhibition
of tumor growth, interference with signal transduction,
induction of apoptosis, and prolongation of mice survival.
As a further confirmation of our preclinical data, we
examined SphK1 expression in tumor specimens from
colorectal cancer patients. To date, SphK1 overexpression
has been described in colorectal cancers compared with
corresponding normal tissues (40), but we reported for the
first time an interesting correlation between SphK1 expres-
sion and poor response to cetuximab therapy. This result
should be interpreted with caution due to the limited
number of patients included in the analysis and it could
be used to design dedicated, prospective clinical trials to
explore the potential role of SphK1 as a biologic marker of
resistance to cetuximab.
Taken together, we show for the first time that SphK1
inhibition is effective in restoring cetuximab antitumor
activity in colorectal cancers resistant to this agent. More-
over, as fingolimod is a clinically available drug (28), the
results of the present study suggest cetuximab plus fingoli-
mod as a novel therapeutic strategy to be tested in the
clinical setting for colorectal cancer patients with resistance
to cetuximab.
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